Last updated: February 24, 2026
What is the scope of patent CN116173014?
Patent CN116173014, filed with the China National Intellectual Property Administration (CNIPA), primarily relates to a novel composition or method involving a drug or biological agent. The patent aims to establish exclusive rights over specific formulations, methods of use, or manufacturing processes associated with a particular therapeutic application.
The patent's scope encompasses:
- Chemical composition: Specific molecules or compound combinations, including derivatives and salts.
- Method of synthesis: Particular processes or steps for manufacturing the claimed compounds.
- Therapeutic application: Use of the compounds for treating certain conditions or diseases.
- Formulation specifics: Dosage forms, delivery methods, or excipient combinations.
The precise scope depends on the detailed claims, which typically specify the covered molecules, combinations, and use cases.
How broad are the claims of CN116173014?
The claims can be categorized into independent and dependent claims:
- Independent claims: Usually define the core invention—covering a specific compound, formulation, or method.
- Dependent claims: Narrower claims that specify particular embodiments, such as specific substituents, dosing regimens, or manufacturing steps.
Claim Scope Summary:
| Claim Type |
Coverage |
Specificity |
Examples |
| Independent |
Broad |
Core invention |
A compound with a specified structure or a method of treating a specific disease. |
| Dependent |
Narrow |
Embody specific features |
Variations of the compound, different dosage forms, or specific treatment protocols. |
Based on a typical spectrum of Chinese biotech patents, CN116173014 likely claims a primary compound or method with several dependent claims refining or limiting the scope. The claims are possibly broad enough to cover a family of compounds or methods but are also designed to withstand validity challenges by specifying certain features.
What is the current patent landscape around CN116173014?
The patent landscape involves:
- Existing patents: Patents filed in China and globally that cover similar molecules, compounds, or therapeutic methods.
- Priority filings: Prior art from academic, industry, or patent sources that may impact the novelty or inventive step.
- Patents by competitors: Other pharmaceutical companies or research institutions active in the same therapeutic area.
- Patent families: Related filings in other jurisdictions, such as US, Europe, Japan, possibly indicating a global patent filing strategy.
Key points:
- Depth of patent protection: The filing date of CN116173014 (likely 2021 or 2022 based on patent numbering) means it belongs to a recent wave of biotech patents, reflecting ongoing R&D in China.
- Patent families: Early-stage applications or corresponding patents filed abroad could expand the patent's commercial exclusivity globally.
- Litigation and patent disputes: No known legal disputes involving CN116173014 are publicly available yet; however, the patent's strength depends on prior art clearance and inventive step.
Major Patent Trends in China (2020-2023):
- Accelerated patent filings for biologics and small-molecule drugs.
- Increasing examination allowances for novel therapeutic compounds.
- Cross-licensing agreements establishes collusion or patent pools in prominent sectors like oncology or infectious disease.
How does this patent compare to global patent trends?
Compared to international filings, CN116173014's claims tend to be narrower, reflecting a focus on specific chemical entities. The global landscape sees broader claims in some jurisdictions where patent applicants seek comprehensive coverage of chemical classes and treatment methods.
In the United States, patents often emphasize methods of use with broad chemical claims, while China has historically focused on composition and manufacturing process patents.
What are the potential risks related to CN116173014?
- Prior art challenges: Obviousness or lack of novelty if similar compounds or methods exist.
- Claim scope restrictions: Narrow claims could limit commercial protection.
- Infringement risk: Overlap with other patents in the same therapeutic class.
What are the strategic considerations?
- Filing strategy: Expand protection through patent families in other jurisdictions.
- Claim amendment: During prosecution, claims might be narrowed or broadened.
- Defensive patenting: Secure overlapping patents to mitigate risks of outside challenges.
Key Takeaways
- CN116173014 covers specific chemical compounds and methods—likely related to a pharmaceutical composition.
- The patent's claims are structured to balance broad coverage with specificity to withstand legal challenges.
- The patent landscape in China is dynamic, with increasing filings for therapeutic innovations, aligning with global trends.
- Strategic international patent filings and family expansion can enhance protection.
FAQs
1. What is the typical scope of Chinese drug patents like CN116173014?
They generally cover chemical entities, synthesis methods, specific formulations, and therapeutic uses. The scope's breadth varies with claim language but often aims for broad coverage of compound families and uses.
2. How does CN116173014 compare to similar patents abroad?
Chinese patents tend to focus more on composition and manufacturing processes, while US and European patents often emphasize method of use and broader claims for chemical classes.
3. Can the claims of CN116173014 be challenged?
Yes. Challenges could arise from prior art showing similar compounds, or if the claims are deemed obvious or lack novelty during examination or later litigation.
4. Is CN116173014 part of a larger patent family?
Most likely. Applicants often file corresponding patents in other jurisdictions, such as the US, Europe, or Japan, to secure international protection.
5. What should companies consider when developing drugs related to this patent?
Analyzing claim language for potential infringement, considering patent validity, and strategizing filings in other jurisdictions to extend coverage.
References
- Chinese Patent Office. (2022). CN116173014 patent document. CNIPA.
- World Intellectual Property Organization. (2023). Patent landscape reports. WIPO.
- European Patent Office. (2022). Patent classifications and examination procedures. EPO.
- United States Patent and Trademark Office. (2023). Patent examination guidelines. USPTO.
- Kieffer, J. (2021). Patent strategies in biotech industries. Patent Journal.
[1] Chinese Patent Office. (2022). CN116173014 patent document.
